ards: the old and the new (-ish)
TRANSCRIPT
© The Children's Mercy Hospital, 2014. 03/14
TARA BENTON, MD MSCIPediatric Intensivist
Children’s Mercy Hospitals and ClinicsJune 27, 2014
Pediatric ARDS: the old and the new(-ish)
© The Children's Mercy Hospital, 2014. 03/142
Disclosures
• none
© The Children's Mercy Hospital, 2014. 03/143
Objectives
• Review history of ARDS
• Define acute lung injury and acute respiratory distress syndrome
• Discuss the epidemiology of pediatric ARDS
• Review relevant pathophysiology
• Discuss ventilator induced lung injury in the context of ARDS
• Discuss available treatment modalities
– In the context of pathophysiology
– Overview of research
© The Children's Mercy Hospital, 2014. 03/144
What I want you to get out of this talk…
• ARDS is a very heterogeneous disease which makes it difficult to study
• Many studies have been performed (mainly in adults) BUT
– ONLY LUNG PROTECTIVE VENTILATION HAS BEEN ACCEPTED AS STANDARD THERAPY AND HAD MORTALITY BENEFIT
• Reducing iatrogenic harm is important
• Children are not small adults
• If you want to do an RCT that people remember, you must have a cool acronym
© The Children's Mercy Hospital, 2014. 03/145
The first description of ARDS?
• 1821 – Laennec (guy who invented the stethoscope) described idiopathic lung anasarca which is pulmonary edema without heart failure in his text ‘A Treatise on Diseases of the Chest’
© The Children's Mercy Hospital, 2014. 03/146
History Lesson
• 1925 – Sir William Osler – considered cause and pathophysiology in his textbook
– ‘uncontrolled septicemia leads to frothy pulmonary edema that resembles serum, not the sanguinous transudative edema fluid seen in dropsy or congestive heart failure’
• 1967 – “Adult” RDS was initially described by Ashbaugh et al in a case series of 12 patients
– Pao2/FiO2 ratio of <300, diffuse bilateral disease, an identifiable insult within 7 days, Pcwp <18 mmHg
– “A” was changed to acute by a consensus conference in 1994
© The Children's Mercy Hospital, 2014. 03/147
DefinitionsAcute lung injury and ARDS (acute respiratory
distress syndrome) are sydromes that represent spectrum of lung disease
Hallmarks of this disease – hypoxia, tachypnea, decreased compliance
Histology – diffuse alveolar damage
© The Children's Mercy Hospital, 2014. 03/148
Definitions1994- American-European Consensus Conference
o ARDS – acute noncardiogenic pulmonary edema with bilateral pulmonary infiltrates on chest x-ray and a ratio of PaO2 to FiO2 of ≤ 200
o ALI – same as above except P/F ratio 200-300o Clinical parameters
Acute onset Severe arterial hypoxemia resistant to oxygen therapy
alone (P/F ratios above) Diffuse pulmonary inflammation No evidence of left atrial hypertension
© The Children's Mercy Hospital, 2014. 03/149
The Berlin Definition 2011Used consensus data as well as empirical data create “new” ARDS criteria
© The Children's Mercy Hospital, 2014. 03/1410
Epidemiology• ARDS occurs in 1-4% of PICU admissions
– As many as 10% of ventilated pts in PICU meet diagnostic criteria for ARDS
• Mortality 20-75% depending on coexisting conditions and risk factors (immunocompromise, nonpulmonary organ failure)
– Seems to be decreasing since the standard practice of low tidal volume ventilation – have been studies with mortality as low as 11%
– General peds mortality 22-26%
– SCT were found to have mortality rate of >75%
• PEDALIEN: 2012 Spain epidemiology study
– Mortality based on P/F ratio >300 = 0%, 200-300= 11.8%, 101-200 = 20.7%, <100 = 38.5%
© The Children's Mercy Hospital, 2014. 03/1411
Epidemiology of ARDS in children
Pneumonia and sepsis most frequent etiologies identified
© The Children's Mercy Hospital, 2014. 03/1412
Pathophysiology
Etiologies:
• Direct injury – – pneumonia, aspiration
• Regional consolidation from destruction of the alveolar architecture
• Indirect injury – – sepsis, shock, cardiopulmonary bypass, transfusion
related acute lung injury (TRALI), pancreatitis
• Pulmonary vascular congestion, interstitial edema, and less severe alveolar involvement
© The Children's Mercy Hospital, 2014. 03/1413
Alveolar-capillary unit in ARDS
Injury →
Inflammatory response →
Proteinaceous fluid filled alveoli and breaks down the alveolar epithelial barrier →
Thick barrier between alveolus and capillary
© The Children's Mercy Hospital, 2014. 03/1414
PathophysiologyPhases of disease
Exudative (Acute) phase
Acute development of decreased pulmonary compliance and arterial hypoxemia tachypneaProinflammatory state
Fibroproliferative phase
Increased alveolar dead space and refractory pulmonary hypertension may develop as a result of chronic inflammation and scarring of alveolar-capillary unit
Recovery phase
Restoration of the alveolar epithelial barrier, gradual improvement in pulmonary compliance and resolution of arterial hypoxemia and eventual return to premorbid pulmonary function
© The Children's Mercy Hospital, 2014. 03/1415
Diagnosis
• Clinical symptoms
– Hypoxia
– Tachypnea
– Eventual respiratory failure
– Other symptoms depend on inciting injury
• Imaging
– CXR – diffuse alveolar infiltrates, air bronchograms
– CT chest- “ground glass opacities,” consolidation along gravitational axis
• Remember diagnostic criteria for ARDS/ALI
© The Children's Mercy Hospital, 2014. 03/1416
Imaging
CXR
© The Children's Mercy Hospital, 2014. 03/1417
Imaging
CT images
© The Children's Mercy Hospital, 2014. 03/14
Targets of Therapy
• Decrease mortality and morbidity
• Hasten recovery• Optimize long-term
cognitive and respiratory function– Minimize profound
hypoxia that leads to cell death and damages developing brain
• MINIMIZE HARM
© The Children's Mercy Hospital, 2014. 03/1419
Therapy options• Supplemental O2
• NIPPV
– HFNC
– CPAP/BiPAP
• Invasive ventilation
– Conventional ventilation
– HFOV
• iNO
• Surfactant
• Steroids
• Prone positioning
• Fluid management
• ECMO
© The Children's Mercy Hospital, 2014. 03/1420
Summary of therapy recommendations
© The Children's Mercy Hospital, 2014. 03/1421
Positive Pressure Ventilation
• Optimize oxygenation while minimizing lung injury
– PEEP to maintain FRC above closing volumes throughout the ventilator cycle (atelectatrauma)
– Limit plateau pressure, Pplat (barotrauma)
– Avoid overdistention (volutrauma)
– Limit radical-related injury due to high concentrations of inspired O2
• Permissive hypercapnea
– Allow Pco2 to rise as long as pH >7.25 (?)
© The Children's Mercy Hospital, 2014. 03/1422
Ventilator Induced Lung Injury• Results from injury to
the blood-gas barrier caused by mechanical ventilation
• Overall suggestion of this study, limit tidal volume (<10ml/kg) in patients with or without ARDS
• Lower rates associated with less VILI
NEJM 2013 Ventilator-Induced Lung Injury
NEJM 2013 Ventilator-Induced Lung Injury
© The Children's Mercy Hospital, 2014. 03/1425
Permissive hypercapnea• Goal is to minimize
VILI
• General consensus is that hypercapnea is not harmful
• pH limit usually set somewhere around 7.25
• Acidosis helps unload oxygen from hemoglobin
© The Children's Mercy Hospital, 2014. 03/1426
Lung Protective Ventilation Strategy
ARDS Network of investigators
• the National Heart, Lung, and Blood Institute, National Institutes of Health, initiated a clinical network to carry out multi-center clinical trials of ARDS treatments
ARDS-Net Trial NEJM 2000
• Sentinel article for lung protective ventilation
• Multicenter RCT enrolled 861 patients with ARDS
– Randomized to low tidal volume (6ml/kg) and low Pplat (<30 cmH2o) vs standard of care (12ml/kg and Pplat 50cm)
• Primary outcome mortality: 31% vs 39.8% p=0007
• Stopped early due to clear benefit of low tidal volume
© The Children's Mercy Hospital, 2014. 03/1427
Lung Protective Strategy
• Meta-analysis of multiple RCTs looking at low vs high tidal volume – Cochrane review 2012
© The Children's Mercy Hospital, 2014. 03/1428
Lung Protective Strategy - meta-analysis
© The Children's Mercy Hospital, 2014. 03/1429
So what makes the difference, high PEEP or low PIP (or Pplat)?
ALVEOLI – ARDS Net NEJM 2004
• RCT 549 with ALI/ARDS
– Low (~8) vs high PEEP (~13)
• Constant tidal volume 6ml/kg and Pplat <30
– Primary outcome – mortality – no difference 24.9 vs 27.5
© The Children's Mercy Hospital, 2014. 03/1430
So what makes the difference, high PEEP or low PIP (or Pplat)?
EXPRESS - Mercat JAMA 2008
• Multicenter RCT 767 adults in France with ALI/ARDS P/F <300
– Minimal distention (PEEP and Pplat kept low) vs recruitment strategy (PEEP adjusted based on airway pressure, Pplat kept <30)
– Primary outcome of mortality was not different between the groups
– Secondary outcomes
• Ventilator free days (7 vs 3 p=0.04)
• Organ failure free days (6 vs 2 p= 0.04)
• Higher compliance, better oxygenation, less use of adjunctive therapies, larger fluid requirements
© The Children's Mercy Hospital, 2014. 03/1431
PEEP strategies
LOVS (lung open ventilation study investigators) JAMA 2008
• Compared established low-tidal-volume ventilation strategy vs experimental strategy which combined low tidal volume, lung recruitment, and high PEEP
– 983 adult patients met ARDS criteria
– Mortality 36.4% vs 40.4% ([RR], 0.90; 95% confidence interval [CI], 0.77-1.05; P = .19
– Lower rates of refractory hypoxemia, death with refractory hypoxemia, and previously defined eligible use of therapies
© The Children's Mercy Hospital, 2014. 03/1432
PEEP and mortality
• Oxygenation Response to PEEP Predicts Mortality in ARDS: A Secondary Analysis of the LOVS and ExPress Trials - Hot of the presses- June 11, 2014 in press from AJRCCM
– Evaluated the physiologic response to PEEP (P/F ratio) and mortality
– Decreased mortality noted for those patients with >25mm Hg increase in P/F ratio following increase in PEEP (OR 0.80, 95% CI 0.72-0.89)
• Stronger association with severe ARDS (P/F ratio <150)
– Findings were supported in data sets from 2 studies
• “We hypothesize that this association may be linked through the physiological causal pathway of increased lung recruitment (reflected by improved oxygenation), protecting against VILI, reducing pulmonary and systemic organ failure, and ultimately lowering mortality.”
© The Children's Mercy Hospital, 2014. 03/1433
History of ARDS research in children
• Why hasn’t a similar sentinel trial been performed in children?
– lack of clinical equipoise
• As in all pediatric research, traditional outcome measures (mortality) would require very large sample size for an adequate study
– Mortality 10-15% most recent trials
– To power a study to detect 25% decrease in mortality -> would need over 2,000 patients
• To detect smaller decrease -> more patients
– PALIVE study – feasibility
• 4 years, 60 PICUs to enroll 800 children to use mortality as endpoint
• Pediatric Acute Lung Injury and Sepsis Investigators (PALISI)
– Collaborative group working on directing multicenter efforts
• Most recent outcome measure in pediatric trials (PALISI) = ventilator free days
© The Children's Mercy Hospital, 2014. 03/1434
High Frequency Oscillatory Ventilation (HFOV)
• Ultimate open lung strategy of ventilation
– very low tidal volume (1-2ml/kg/cycle), high mean airway pressure (low PIP)
• Used frequently in pediatrics (adopted from NICU)
• Early data in adults indicated that HFOV might be beneficial (however this was compared to high tidal volume conventional ventilation)
• Only one crossover trial in pediatrics (Arnold, et al CCM 1994) comparing rescue HFOV with conventional ventilation
– HFOV associated with higher MAPs, improved oxygenation, reduced need for O2 at 30 days
© The Children's Mercy Hospital, 2014. 03/1435
HFOV vs conventional ventilation
• In adults, two recent RCTs of HFOV vs low tidal volume high PEEP published in the NEJM demonstrated no mortality benefit and in one of the trials may have shown harm (higher mortality)
– OSCILLATE – multicenter RCT – 39 ICUs in 5 countries
• Moderate to severe ARDS (P/F ratio <200, FiO2 >0.5)
• HFOV targeting lung recruitment vs conventional ventilation targeting lung recruitment (low tidal volume, high PEEP)
• Primary outcome in-hospital mortality: HFOV 47% vs 35% (RR of death 1.33 with HFOV CI 1.09 to 1.64; p=0.005)
• Stopped early
• Should we be reconsidering our “lung protection”
© The Children's Mercy Hospital, 2014. 03/1436
Open Lung Ventilation – adverse effects
• Important hemodynamic considerations
– Increases intrathoracic pressure
• Decrease venous return to right atrium (preload) – lead to low cardiac output
• Support this with fluid, inotropes might be necessary
– Depending on how high MAP, might need muscle relaxation
© The Children's Mercy Hospital, 2014. 03/14
Prone positioning
Goal of prone positioning is to improve V/Q matching.
© The Children's Mercy Hospital, 2014. 03/1438
Prone positioning
• Curley, et al. JAMA 2005
– Multicenter RCT 102 pediatric patients with ALI/ARDS
– Randomized to prone for 20hrs vs supine
– Stopped early due to futility
– No improvement in other secondary outcomes
• In adults, studies suggested that in the sub-group of more severe ARDS, prone positioning might be beneficial
© The Children's Mercy Hospital, 2014. 03/1439
Prone positioning
Guerin, et al in NEJM May 2013 (France and Spain)
– Multicenter prospective RCT – 466 pts with severe ARDS (P/F <150, FiO2 >0.6, PEEP >5, tidal volume 6ml/kg, Pplat <30) , enrolled at <36hrs of ventilation
• Prone-positioning for at least 16 hours vs standard supine
• Primary outcome 28 day mortality
– Prone 16% vs supine 32.8% (p<0.001)
– HR for death with prone positioning 0.39 [95%CI 0.29-0.63]
• Unadjusted 90 day mortality = 23.6% prone vs 41% supine (p<0.001)
© The Children's Mercy Hospital, 2014. 03/1440
Guerin, et al – early prone position
© The Children's Mercy Hospital, 2014. 03/1441
Inhaled Nitric Oxide (iNO)
• Potent selective vasodilator
– Goal is to improve V/Q matching by directing blood toward the more open alveoli
• Meta-analysis of multiple studies (children and adults)
– Improves oxygenation without improving chosen outcomes
© The Children's Mercy Hospital, 2014. 03/1442
iNO – mortality
© The Children's Mercy Hospital, 2014. 03/1443
iNO – oxygenation
© The Children's Mercy Hospital, 2014. 03/1444
Surfactant
• Surfactant –produced by Type II alveolar cell
– Reduces surface tension at the air: fluid interface and varies surface tension during the respiratory cycle
– WOB minimized, atelectasis at end expiration prevented, distribution of ventilation is equal during inspiration
• Early studies showed promise
© The Children's Mercy Hospital, 2014. 03/1445
Surfactant
• PALISI study Calfactant in pediatric ARDS – PCCM 2013
– Multicenter RCT 110 pts with ARDS due to direct lung injury
– Randomized to calfactant vs air within 48 hours of intubation (up to 3 doses)
– Stopped early due to futility
– Overall mortality was 11%
– Not associated with improvement in oxygenation
© The Children's Mercy Hospital, 2014. 03/1446
Steroids
No studies in pediatricsAdult studies indicate no improvement with treating in the acute phase (and might be harmful if used for “prevention”)Outcomes contradictory in many other studies (including meta-analysis)
Preventive steroids Therapeutic steroids
Steroids – meta-analysis Cochrane review 2008
© The Children's Mercy Hospital, 2014. 03/1448
Restrictive Fluid Management
• ARDSNet FACTT trial
– Conservative approach to fluid management increase VFDs and improves oxygenation in adults with ALI/ARDS when compared to more liberal fluid protocol
• Albumin + lasix - might be helpful in adults
• Should only be used after adequate initial resuscitation from shock
© The Children's Mercy Hospital, 2014. 03/1449
Restrictive Fluid Management
• Calfactant Trial secondary analysis
• Guideline was for conservative fluid management based on modified FACTT trail
• Conclusion - In pediatrics we are still fairly liberal, those patients that died were more fluid overloaded
© The Children's Mercy Hospital, 2014. 03/1450
Sedation and Muscle Relaxation
• No studies about appropriate type of sedation
– RESTORE data hopefully coming soon?
• Muscle relaxation – associated with weakness and critical illness myopathy in adult patients with ALI
– If concurrent use with steroids -> increases this risk?
– Early might be ok, but not prolonged
– Only use if necessary for oxygenation or ventilation
© The Children's Mercy Hospital, 2014. 03/1451
ECMO• Has been used as a rescue therapy for many years
• Recent adult study (CESAR Trial) showed benefit for ECMO use in adults with ARDS
– Survival at 6 months in ECMO 63% vs Conventional group 47%
• Another trial (ECMO to Rescue Lung Injury in severe ARDS – EOLIA) ongoing and anticipated to be completed this year
• Strategy and thoughts are changing about ECMO use
– What is lung rest?
– Extubation?
– Early mobilization
– Limit sedation/muscle relaxation
© The Children's Mercy Hospital, 2014. 03/1452
Novel Therapies
• Statins in sepsis induced ARDS (NEJM May, 2014)
– Statins are typically used to reduce cholesterol levels, but have been found to reduce inflammation
– Animal models have suggested that statins can prevent ARDS
– Human studies have suggested that statins used in sepsis or other inflammatory conditions improves outcome
– RCT of rosuvastatin vs placebo in adults with sepsis-induced ARDS
• Stopped for futility with ~75% of enrollment (745 patients)
• No mortality difference
• Increased incidence of renal and hepatic dysfunciton with statins
© The Children's Mercy Hospital, 2014. 03/1453
Novel Therapies
• Mesenchymal Stem Cells in Mouse and Sheep ARDS models have improved oxygenation and decreased pulm edema
– Mesenchymal stem cells have been shown to modulate the inflammatory response, augment tissue repair, enhance pathogen clearance, and reduce severity of injury, pulmonary dysfunction, and death
© The Children's Mercy Hospital, 2014. 03/1454
How are we practicing as pediatric intensivists?
• PALIVE PCCM 2013
• Survey sent out to multiple centers across US and Europe
• 3 case scenarios asking pediatric intensivists parameters they would use to manage the patients
• Bottom line: most use adult guidelines
© The Children's Mercy Hospital, 2014. 03/1455
How do we practice?
© The Children's Mercy Hospital, 2014. 03/1456
How do we practice?
Optimal PaCO2 levels Adjunctive treatments considered
© The Children's Mercy Hospital, 2014. 03/1457
How do we practice?
• The same group gathered actual data from the institutions and there was a discrepancy between the survey results and actual practice
– 25% of patients were ventilated with Vt >10ml/kg
– 16% had PIPs greater than 35cm H2O
• The conclusion of the group – though pediatric physicians agree generally with the adult guidelines, it is difficult in practice to maintain those parameters
– Even with protocols in clinical studies the compliance is usually between 66-87%
© The Children's Mercy Hospital, 2014. 03/1458
Summary• Pediatric ARDS is less common than in adults, but still accounts for a
large portion of our ventilated patients
• Most common etiologies are pneumonia and sepsis
• Lung protective ventilation is the ONLY therapeutic strategy that has showed reproducible mortality benefit
– Low tidal volume, low Pplat, high PEEP
– Permissive hypercapnea
• Likely there are subgroups of patients (i.e. severe ARDS) that benefit from additional therapeutic strategies (prone positioning, HFOV, iNO, etc.)
• More pediatric research is needed but difficult to organize and perform
© The Children's Mercy Hospital, 2014. 03/1459
So what’s new?
• Trying to determine appropriate inclusion criteria for clinical trials and appropriate clinical outcomes
– Thought is that many of the therapies that have been studies likely have benefit if we can identify the right group of patients
• Think early about minimizing harm (lung protection)
• ECMO
– Using more protocolized lung protection to determine if this is a better strategy and improves outcomes.
• Continuing search for biomarkers for ARDS to potentially help with future studies
• Continuing search for novel therapies
© The Children's Mercy Hospital, 2014. 03/1460
References• ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA
2012;307:2526-33.
• Lopez-Fernandex Y, et al. PED-ALIEN Network. Pediatric Acute Lung Injury Epidemiology and Natural History Study: Incidence and outcome of the acute respiratory distress syndrome in children. Crit Care Med 2012:40 (12);3238-3245
• Smith LS, Zimmerman JJ. Mechanisms of Acute Respiratory Distress Syndrome in Children and Adults: A Review and Suggestions for Future Research. Ped Crit Care Med 2013: 14; 631-643
• Biehl M, Kashiouris MG, Gajic O. Ventilator-Induced Lung Injury: Minimizing its Impact in Patients With or at Risk for ARDS. Respir Care 2013;8(6): 927-934.
• Slutsky AS, Ranieri VM. Ventilatory-Induced Lung Injury. N Engl J Med 2013;369: 2126-2136
• Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000;342:1301–1308
• Petrucci N, De Feo C. Lung protective ventilation strategy for the acute respiratory distress syndrome (Review). The Cochrane Library 2013:2; 1-36
• Mercat A, Richard J, Vielle B, Jaber S. Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2008;299:646–655.
• Meade MO, Cook DJ, Guyatt GH, Slutsky AS, Arabi YM, Cooper DJ, Davies AR, Hand LE, Zhou Q, Thabane L, Austin P, Lapinsky S, Baxter A, Russell J, Skrobik Y, Ronco JJ, Stewart TE, Lung Open Ventilation Study Investigators. Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2008;299:637–645.
© The Children's Mercy Hospital, 2014. 03/1461
References• Ferguson ND, et al. OSCILLATE Trial Investigators and the Canadian Critical Care Trials Group. High-Frequency Oscillation in Early
Acute Respiratory Distress Syndrome. N Engl J Med 2013
• Goligher, et al. Oxygenation Response to PEEP Predicts Mortality in ARDS: A Secondary Analysis of the LOVS and ExPress Trials. AJRCCM 2014 in press
• Guerin C, Reignier J, et al. PROSEVA Study Group. Prone Positioning in Severe Acute Respiratory Distress Syndrome. N Engl J Med 2013: 368(23); 2159-2168
• Willson DF, et al. PALISI Network. Pediatric Calfactant in Acute Respiratory Distress Syndrome Trial. Ped Crit Care Med 2013: 14(7); 658-665
• Peter V, et al. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome in adults: meta-analysis. BMJ 2008 1-10
• Wiedemann HP, Wheeler AP, Bernard GR, et al: Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006;354:2564–2575
• Willson DF, et al. PALISI Network. The relationship of fluid administration to outcome in the Pediatric Calfactant in Acute Respiratory Distress Syndrome Trial. Ped Crit Care Med 2013: 14(7); 666-672
• Rosuvastain for Sepsis-Associated Acute Respiratory Distress Syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2014;370:2191-2200
• Assmussen S, et al. Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia. Thorax 2014 Jun 2 in press
• Santschi M, Randolph A, et al. PALIVE, PALISI, and ESPNIC investigators. Mechanical Ventilation Strategies in Children with Acute Lung Injury: A Survey on Stated Practice Pattern. Pediatr Crit Care Med 2012; 14:e332–e337
© The Children's Mercy Hospital, 2014. 03/1462
Thank you!